Last reviewed · How we verify
ABT-493
ABT-493 is a protease inhibitor.
ABT-493 is a protease inhibitor. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | ABT-493 |
|---|---|
| Also known as | glecaprevir, Glecaprevir |
| Sponsor | AbbVie |
| Drug class | protease inhibitor |
| Target | NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the NS3/4A protease of the hepatitis C virus, preventing viral replication.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (PHASE2, PHASE3)
- Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (PHASE3)
- A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (PHASE3)
- A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (PHASE3)
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-493 CI brief — competitive landscape report
- ABT-493 updates RSS · CI watch RSS
- AbbVie portfolio CI